ProKidney Corp. (PROK)

2.3000 +0.1800 (+8.49%) At close: 04:00PM EDT

ProKidney Corp.

2000 Frontis Plaza Blvd.
Suite 250
Winston-Salem, NC 27103
United States
336 999 7028
https://www.prokidney.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 163

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Timothy A. Bertram D.V.M., Ph.D.	Founder	970.4k	N/A	1955
Mr. Todd C. Girolamo Esq., J.D., M.B.A.	Chief Legal Officer & Secretary	600.17k	N/A	1965

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Corporate governance

ProKidney Corp.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 10; Board: 7; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.